Day: March 7, 2023

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 7, 2023, 8:30 a.m. ET  Newly rebranded Zevra Therapeutics well positioned to become a commercially focused rare disease company Arimoclomol NDA resubmission on track to be filed as early as Q3 2023 KP1077 Phase 2 Trial on track to deliver preliminary data as early as Q3 2023 and top-line data as early as year-end 2023 AZSTARYS® royalty revenue growing with one or more revenue milestones expected to be achieved in 2023 Strong balance sheet with cash, cash equivalents and investments of $102.9 million which extends the cash runway into 2026 CELEBRATION, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its...

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. “Highlighted by strong fourth quarter revenue results and last week’s acquisition of the Coflex® product line, we are executing on our key growth initiatives,” said Sean Browne, President and CEO of Xtant Medical. “We continue to generate robust demand for our biologics products, which grew 14% for the quarter, and improve our operating efficiencies by increasing our production capacity that now has us well-positioned to sustain our momentum in 2023. Additionally, with the addition of the Coflex product line, we significantly...

– Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients – – Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens – – Strong cash position of $173.3 million supports operations into mid-2025 –   LONDON, March 07, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights. “In 2022, we were pleased to deliver early proof-of-concept data supporting the promise of our clonal neoantigen-reactive T cell, or...

Total revenues of $730.2 million, up 21.5% and System-wide sales of $914.8 million, up 21.9% Same-restaurant sales growth of 14.5% and Same-restaurant traffic growth of 7.7% Income from operations margin of 2.4% and Restaurant level operating profit margin of 17.9% 43 system-wide restaurants opened across 16 statesBRADENTON, Fla., March 07, 2023 (GLOBE NEWSWIRE) — Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended December 25, 2022 (“Q4 2022”) and fiscal year ended December 25, 2022 (“2022”) compared to the thirteen weeks ended December 26, 2021 (“Q4 2021”) and fiscal year ended December 26, 2021 (“2021”) and provided an outlook for the fiscal year ending December 31,...

Fr8Tech’s Q4 2022 Performance: Strong Fr8Fleet Results Counterbalance Dip in Shipments from Key Account HOUSTON, March 07, 2023 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT) (“Fr8Tech”), a technology company offering its custom-developed Fr8App, an industry-leading freight-matching platform powered by AI and machine-learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region, today reports fourth quarter 2022 revenue for the period ended Dec. 31, 2022. Fr8Tech reported $4.4 million in quarterly revenue for Q4 2022, and YTD 2022 revenue reached an impressive $25.9 million, up 20.6% from the prior year. With eyes set firmly on the future, Fr8Tech’s management announced 2023 revenue guidance of $36 million, representing almost 40% growth from Fr8App’s...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track for next data update at a medical conference in mid-2023 with a Biologics License Application (BLA) submission to the US FDA planned by end of the yearObe-cel data presented at ASH demonstrated 35% of relapsed/refractory adult ALL patients in the ALLCAR19 study remain in complete remission at a median follow up of 36 months without the need for additional anti-leukemia therapyPotentially best-in-class profile of obe-cel supported by data observed in non-Hodgkin lymphoma (NHL) patients in the ALLCAR19 study, with continued high levels of clinical activity and an encouraging tolerability profile across DLBCL, MCL, FL and CLLFunds secured...